Bioimpacts. 2019;9(1):1-3.
doi: 10.15171/bi.2019.01
  Abstract View: 101
  PDF Download: 20

Editorial

Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities

Nastran Hashemzadeh 1,2, Khosro Adibkia 1,3 ORCiD, Jaleh Barar 1,3 * ORCiD

1 Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2 Students' Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Trafficking of macromolecular immunotherapy agent to the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme, catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negatively regulate the activity of T cells. Thus, this pathway, in particular, Trp/Kyn, can be targeted with novel treatment modalities such as IDO1 inhibitor to benefit patients with aggressive solid tumors.
First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 101

Your browser does not support the canvas element.


PDF Downloaded: 20

Your browser does not support the canvas element.

Submitted: 07 Oct 2018
Accepted: 08 Oct 2018
First published online: 21 Oct 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)